** Abbott ABT.N warned on Thursday it expects more than $1 billion in financial headwinds this year from a sharp decline in COVID-19 testing demand, new U.S. tariffs and government's foreign aid freeze
** The medical device giant forecast third-quarter profit below estimates
TEMPORARY CHALLENGES
** J.P.Morgan ("overweight," PT: $140) views downwards growth revisions for Abbott as a one-off event rather than signs of weakening fundamentals in the business
** TD Cowen ("buy," PT: $145) says ABT is on track for over 10% EPS growth this year despite hurdles and tariffs, as key fundamentals remain reliable
** Piper Sandler ("overweight," PT: $150) sees potential for revenue growth next year, led by new product launches such as dual-analyte sensor, Volt U.S. launch and Alinity, as headwinds from the diagnostics business abate
** Jefferies ("buy," PT: $145) says they're constructive on ABT's fundamentals and expect benefits from new product launches to overshadow existing headwinds
(Reporting by Kanchana Chakravarty in Bengaluru)
((Kanchana.Chakravarty@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.